Open Access

Low expression of SEMA4D as a potential predictive molecular marker of poor survival in patients with melanoma combined with liver cancer

  • Authors:
    • Xiang Liu
    • Chong Zhang
    • Wu-Han Yang
    • Sheng-Chao Li
    • Rui-Feng Wang
    • Yi-Bin Zhang
    • Zhi-Lei Zhang
  • View Affiliations

  • Published online on: March 7, 2023     https://doi.org/10.3892/ol.2023.13746
  • Article Number: 160
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This study explored the correlation between semaphorin 4D (SEMA4D) and the prognosis and survival time of patients with melanoma combined with liver cancer. A total of 272 patients were recruited, and clinical and follow‑up data were recorded. The expression levels of SEMA4D and SEMA3B were determined. Pearson's χ2 test and Spearman's rank correlation coefficient were used to analyze the relationship between prognosis and the assessed parameters of melanoma patients. Univariate and multivariate Logistic regression and Cox proportional risk regression analyses were used for further analysis. Additionally, receiver operating characteristic curve and survival curves of subjects were plotted. The Pearson's χ2 test showed that the prognosis of melanoma patients was significantly correlated with age, tumor grade, and decreased SEMA4D expression. Additionally, Spearman's correlation coefficient analysis showed that age, tumor grade, and SEMA4D expression were significantly correlated with prognosis. Univariate logistic regression analysis showed that age and tumor grade, and SEMA4D expression, were significantly correlated with prognosis. Older patients, a higher tumor grade, and lower SEMA4D expression were associated with a poorer prognosis. Multivariate logistic regression analysis showed that older patients had a poorer prognosis, and patients with lower SEMA4D expression levels had a significantly worse prognosis than patients with higher SEMA4D expression levels. Kaplan‑Meier analysis showed that the survival time of older patients was lower than that of the younger patients. The survival times of patients with lower SEMA4D expression levels were significantly lower than that of patients with higher SEMA4D expression levels. Multivariate Cox regression analysis showed that the survival time of older patients was lower than that of younger patients. The survival time of melanoma patients with low SEMA4D expression was significantly lower than that of patients with higher SEMA4D expression. SEMA4D was significantly associated with melanoma, and lower SEMA4D expression was associated with a poorer survival prognosis in melanoma patients.
View Figures
View References

Related Articles

Journal Cover

April-2023
Volume 25 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu X, Zhang C, Yang W, Li S, Wang R, Zhang Y and Zhang Z: Low expression of SEMA4D as a potential predictive molecular marker of poor survival in patients with melanoma combined with liver cancer. Oncol Lett 25: 160, 2023
APA
Liu, X., Zhang, C., Yang, W., Li, S., Wang, R., Zhang, Y., & Zhang, Z. (2023). Low expression of SEMA4D as a potential predictive molecular marker of poor survival in patients with melanoma combined with liver cancer. Oncology Letters, 25, 160. https://doi.org/10.3892/ol.2023.13746
MLA
Liu, X., Zhang, C., Yang, W., Li, S., Wang, R., Zhang, Y., Zhang, Z."Low expression of SEMA4D as a potential predictive molecular marker of poor survival in patients with melanoma combined with liver cancer". Oncology Letters 25.4 (2023): 160.
Chicago
Liu, X., Zhang, C., Yang, W., Li, S., Wang, R., Zhang, Y., Zhang, Z."Low expression of SEMA4D as a potential predictive molecular marker of poor survival in patients with melanoma combined with liver cancer". Oncology Letters 25, no. 4 (2023): 160. https://doi.org/10.3892/ol.2023.13746